The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission, a mechanism thought to contribute to ...

(JAMA Network Open) As an FDA decision nears on the muscarinic agonist xanomeline-trospium for schizophrenia -- which could ...

The US regulator has set an action date of 26th September next year for a decision on KarXT, which combines muscarinic agonist xanomeline tartrate and muscarinic antagonist trospium chloride ...